Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  Vij, Neeraj ^a,b   Min, Taehong ^a   Marasigan, Rhul ^a   Belcher, Christopher N ^a   Mazur, Steven ^a   Ding, Hong ^c   Yong, Ken Tye ^c   Roy, Indrajit ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY ASSAYS; ANTI-INFLAMMATORIES; BIODEGRADABLE NANOPARTICLE; BIODISTRIBUTIONS; BORTEZOMIB; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATORS; DRUG DELIVERY SYSTEM; DRUG RELEASE; IMMUNE RESPONSE; IN-VITRO; IN-VIVO; INTRANASAL; LUNG DISEASE; MULTIPLE PROCESS; OPTICAL IMAGING; PATHOPHYSIOLOGY; PLGA NANOPARTICLES; POST TREATMENT; PROTEASOMAL PATHWAY; PROTEASOME INHIBITORS; PROTEASOMES; PSEUDOMONAS AERUGINOSA; RELEASE KINETICS; SELECTIVE INHIBITION; SELECTIVE INHIBITORS; TEMPERATURE-SENSITIVE; THERAPEUTIC EFFICACY; THERAPEUTIC TARGETS; VELCADE; WHOLE-BODY;

AMINO ACIDS; ANIMALS; BIODEGRADATION; BIOLOGICAL ORGANS; CHLORINE COMPOUNDS; DEGRADATION; NANOPARTICLES;

CONTROLLED DRUG DELIVERY;

BORTEZOMIB; POLYGLACTIN; PROTEASOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYSTIC FIBROSIS; DRUG DEGRADATION; DRUG DISTRIBUTION; ENZYME ACTIVITY; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SLOW DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TRANSMISSION ELECTRON MICROSCOPY; WHOLE BODY IMAGING;

ANIMALIA; MURINAE; MUS; PSEUDOMONAS AERUGINOSA;

EID: 77956930518     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-22     Document Type: Article

References (40)

1. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83:121-127. 10.1016/0092-8674(95)90240-6, 7553863.
2. Mitchell BS. The proteasome--an emerging therapeutic target in cancer. N Engl J Med 2003, 348:2597-2598. 10.1056/NEJMp030092, 12826633.
3. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004, 10:3954-3964. 10.1158/1078-0432.CCR-03-0781, 15217925.
4. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8:508-513. 10.1634/theoncologist.8-6-508, 14657528.
5. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001, 28:613-619. 10.1016/S0093-7754(01)90034-X, 11740819.
6. Zhang LN, Karp P, Gerard CJ, Pastor E, Laux D, Munson K, Yan Z, Liu X, Godwin S, Thomas CP, et al. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Mol Ther 2004, 10:990-1002. 10.1016/j.ymthe.2004.08.009, 15564131.
7. Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem 1998, 273:3562-3573. 10.1074/jbc.273.6.3562, 9452483.
8. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647. 10.1074/jbc.M200360200, 11872748.
9. Vij N, Fang S, Zeitlin PL. Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues {Delta}F508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels: THERAPEUTIC IMPLICATIONS. J Biol Chem 2006, 281:17369-17378. 10.1074/jbc.M600509200, 16621797.
10. Davis SS. Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. Trends Biotechnol 1997, 15:217-224. 10.1016/S0167-7799(97)01036-6, 9183864.
11. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347. 10.1016/S0169-409X(02)00228-4, 12628320.
12. Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 2004, 21:641-648. 10.1023/B:PHAM.0000022411.47059.76, 15139521.
13. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 2009, 30:2790-2798. 10.1016/j.biomaterials.2009.01.057, 19232712.
14. Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 2010, 6:237-244.
15. Vij N, Amoako MO, Mazur S, Zeitlin PL. CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2008, 38:176-184. 10.1165/rcmb.2007-0197OC, 2214673, 17709599.
16. Vij N. AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential. J Cell Mol Med 2008, 12:2511-2518. 10.1111/j.1582-4934.2008.00462.x, 18798739.
17. Vij N, Mazur S, Zeitlin PL. VCP is involved in ERAD and aggresome formation of ΔF508-CFTR. Pediatric Pulmonology 2006, 41:209.
18. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008, 319:916-919. 10.1126/science.1141448, 18276881.
19. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR, Segatori L, Kelly JW. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134:769-781. 10.1016/j.cell.2008.06.037, 2650088, 18775310.
20. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998, 95:15671-15676. 10.1073/pnas.95.26.15671, 28102, 9861028.
21. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995, 2:493-506. 10.1016/1074-7613(95)90030-6, 7538441.
22. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977, 146:1585-1602. 10.1084/jem.146.6.1585, 2181919, 336836.
23. Fang J, Sawa T, Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49. full_text, 12675206.
24. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603. 10.1126/science.8128245, 8128245.
25. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002, 82:105-114. 10.1016/S0168-3659(02)00127-X, 12106981.
26. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996, 93:14164-14169. 10.1073/pnas.93.24.14164, 19511, 8943078.
27. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004, 56:1273-1289. 10.1016/j.addr.2003.12.004, 15109769.
28. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999, 103:309-312. 10.1172/JCI6222, 407906, 9927490.
29. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 2008, 5:629-639. 10.1517/17425247.5.6.629, 18532919.
30. Yang W, Peters JI, Williams RO. Inhaled nanoparticles--a current review. Int J Pharm 2008, 356:239-247. 10.1016/j.ijpharm.2008.02.011, 18358652.
31. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005, 11:56-62. 10.1038/nm1174, 15619625.
32. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, Finkbeiner WE, Widdicombe JH, Gruenert DC. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994, 10:38-47.
33. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, Gruenert DC. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 2002, 9:683-685. 10.1038/sj.gt.3301741, 12032687.
34. Van Heeckeren AM, Scaria A, Schluchter MD, Ferkol TW, Wadsworth S, Davis PB. Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection. Am J Physiol Lung Cell Mol Physiol 2004, 286:L717-726. 10.1152/ajplung.00227.2003, 14514520.
35. van Heeckeren AM, Schluchter MD, Xue W, Davis PB. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med 2006, 173:288-296. 10.1164/rccm.200506-917OC, 2662931, 16272448.
36. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001, 116:637-646. 10.1309/44HW-5YCJ-FLLP-3R56, 11710679.
37. Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009, 68:1761-1767. 10.1136/ard.2008.097709, 19054826.
38. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS ONE 2009, 4:e4664. 10.1371/journal.pone.0004664, 2647738, 19247502.
39. Wu F, Vij N, Roberts L, Lopez S, Joyce S, Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 2007, 7;282(36):26409-17.
40. Singh G, Katyal SL. An immunologic study of the secretory products of rat Clara cells. J Histochem Cytochem 1984, 32:49-54.